Cytodel
Pre-clinicalCytoDel Inc.'s patented and proprietary technology platform is based on producing recombinant derivatives of botulinum neurotoxin (BoNT) engineered to create high value products with customized properties, and to deliver active agents to therapeutic targets inside neurons.
Founded
2017
Focus
Biosimilars
About
CytoDel Inc.'s patented and proprietary technology platform is based on producing recombinant derivatives of botulinum neurotoxin (BoNT) engineered to create high value products with customized properties, and to deliver active agents to therapeutic targets inside neurons.
Funding History
2Total raised: $4M
Seed$3.2MUndisclosedMay 15, 2020
Grant$800KNIH SBIRJun 15, 2019
Company Info
TypePrivate
Founded2017
LocationCambridge, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile